A randomized, double‐blind, placebo‐controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial‐onset seizures

• Published in: Epilepsia (Copenhagen) 2011-04, Vol.52 (4), p.816-825
• Main Authors: Halford, Jonathan J., Ben‐Menachem, Elinor, Kwan, Patrick, Ness, Seth, Schmitt, Jennifer, Eerdekens, Mariëlle, Novak, Gerald
• Format: Article
• Language: English
• Subjects: Adjunctive treatment; administration & dosage; Adult; adverse effects; Anticonvulsants; Anticonvulsants - administration & dosage; Anticonvulsants - adverse effects; Anticonvulsants. Antiepileptics. Antiparkinson agents; Biological and medical sciences; Carbamates; Carbamates - administration & dosage; Carbamates - adverse effects; Carisbamate; Combination; diagnosis; Double-Blind Method; Drug Administration Schedule; Drug dosages; Drug Therapy; Drug Therapy, Combination - methods; Epilepsies; Epilepsies, Partial - diagnosis; Epilepsies, Partial - drug therapy; Epilepsy; Female; Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy; Humans; Male; MEDICAL AND HEALTH SCIENCES; Medical sciences; MEDICIN OCH HÄLSOVETENSKAP; methods; Middle Aged; Nervous system (semeiology, syndromes); Neurology; Neuropharmacology; Outcome Assessment (Health Care); Outcome Assessment (Health Care) - methods; Partial; Partial‐onset seizures; Pharmacology. Drug treatments
• ISSN: 0013-9580; 1528-1167; 1528-1167
• DOI: 10.1111/j.1528-1167.2010.02960.x

Summary Purpose:  To assess the efficacy, safety, and tolerability of adjunctive carisbamate treatment at 800 mg/day and 1,200 mg/day in patients with partial‐onset seizures (POS). Methods:  Patients ≥16 years of age with an established diagnosis of POS for ≥1 year and uncontrolled on one to three antiepileptic drugs were enrolled. Eligible patients remained on stable doses of prescribed antiepileptic drugs for an 8‐week pretreatment baseline phase and were then randomized (1:1:1) to receive carisbamate (800 mg/day or 1,200 mg/day), or placebo, for a 14‐week double‐blind phase. Primary efficacy endpoints were percentage reduction in POS frequency and responder rate (patients with ≥50% reduction in POS frequency) during the double‐blind versus baseline phase. Key Findings:  Five hundred forty‐seven patients were randomized; 540 composed the intent‐to‐treat (ITT) analysis. Four hundred thirty‐four patients (79%) completed the study. The median percent reduction from baseline to treatment phase in POS frequency was: 21% (placebo); 30% (carisbamate 800 mg); 36% (carisbamate 1,200 mg), and 32% (combined carisbamate doses). The combined carisbamate dose group was not significantly different from placebo for the median percent reduction of POS frequency (p = 0.20) or responder rate (p = 0.18). Therefore, the difference from placebo for the individual carisbamate dose groups was also considered nonsignificant, based on a prespecified step‐down analysis. Dizziness was the most common treatment‐emergent adverse event, with a higher incidence (≥5% difference) in the combined carisbamate group (31%) than placebo (9%); the incidence was higher with carisbamate 1,200 mg (32%, n = 58) than with carisbamate 800 mg (30%, n = 53). Significance:  Adjunctive carisbamate therapy in patients with POS did not demonstrate efficacy across the dose range assessed versus placebo. No new safety findings were observed.